AU774580B2 - Assay with reduced background - Google Patents
Assay with reduced background Download PDFInfo
- Publication number
- AU774580B2 AU774580B2 AU23071/00A AU2307100A AU774580B2 AU 774580 B2 AU774580 B2 AU 774580B2 AU 23071/00 A AU23071/00 A AU 23071/00A AU 2307100 A AU2307100 A AU 2307100A AU 774580 B2 AU774580 B2 AU 774580B2
- Authority
- AU
- Australia
- Prior art keywords
- analyte
- adenylate kinase
- assay
- atp
- thermostable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000003556 assay Methods 0.000 title claims abstract description 89
- 230000002829 reductive effect Effects 0.000 title description 8
- 102000002281 Adenylate kinase Human genes 0.000 claims abstract description 121
- 108020000543 Adenylate kinase Proteins 0.000 claims abstract description 121
- 239000012491 analyte Substances 0.000 claims abstract description 102
- 239000005089 Luciferase Substances 0.000 claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 20
- 238000005406 washing Methods 0.000 claims abstract description 19
- 108060001084 Luciferase Proteins 0.000 claims abstract description 18
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims abstract description 17
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 17
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 17
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims abstract description 16
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims abstract description 16
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 238000010438 heat treatment Methods 0.000 claims abstract description 10
- 239000011230 binding agent Substances 0.000 claims abstract description 4
- 239000007790 solid phase Substances 0.000 claims description 70
- 102000004190 Enzymes Human genes 0.000 claims description 45
- 108090000790 Enzymes Proteins 0.000 claims description 45
- 238000012360 testing method Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 25
- 108091006112 ATPases Proteins 0.000 claims description 22
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 22
- 102000029797 Prion Human genes 0.000 claims description 21
- 108091000054 Prion Proteins 0.000 claims description 21
- 244000005700 microbiome Species 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 102000001253 Protein Kinase Human genes 0.000 claims description 5
- 230000002779 inactivation Effects 0.000 claims description 5
- 108060006633 protein kinase Proteins 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000523 sample Substances 0.000 description 64
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 45
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 44
- 238000000034 method Methods 0.000 description 30
- 238000011534 incubation Methods 0.000 description 22
- 239000011324 bead Substances 0.000 description 20
- 238000001514 detection method Methods 0.000 description 19
- 238000005415 bioluminescence Methods 0.000 description 15
- 230000029918 bioluminescence Effects 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 10
- 102000011923 Thyrotropin Human genes 0.000 description 10
- 108010061174 Thyrotropin Proteins 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 108010007730 Apyrase Proteins 0.000 description 9
- 102000007347 Apyrase Human genes 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- 208000010544 human prion disease Diseases 0.000 description 7
- 230000009871 nonspecific binding Effects 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 108030001720 Bontoxilysin Proteins 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 5
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 5
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 5
- 208000024777 Prion disease Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000186339 Thermoanaerobacter Species 0.000 description 3
- 108030003004 Triphosphatases Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 229940053031 botulinum toxin Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005202 decontamination Methods 0.000 description 3
- 230000003588 decontaminative effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 229940125532 enzyme inhibitor Drugs 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- 241000726121 Acidianus Species 0.000 description 2
- 241000620141 Carboxydothermus Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- 241000605233 Hydrogenobacter Species 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000003390 bioluminescence detection Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical class O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 2
- 239000002359 drug metabolite Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YOVRGSHRZRJTLZ-HZPDHXFCSA-N 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(C(O)=O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YOVRGSHRZRJTLZ-HZPDHXFCSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 229940093764 Adenylate kinase inhibitor Drugs 0.000 description 1
- 241000567147 Aeropyrum Species 0.000 description 1
- 241000147157 Ammonifex Species 0.000 description 1
- 241000207208 Aquifex Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000205046 Archaeoglobus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 241000178972 Caloramator Species 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000192733 Chloroflexus Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000971513 Coprothermobacter Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000205236 Desulfurococcus Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000531184 Ferroglobus Species 0.000 description 1
- 241000206212 Fervidobacterium Species 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 241001135645 Geotoga Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000531259 Hyperthermus Species 0.000 description 1
- 102100025818 Major prion protein Human genes 0.000 description 1
- 101710138751 Major prion protein Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000921347 Meiothermus Species 0.000 description 1
- 241000202974 Methanobacterium Species 0.000 description 1
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 1
- 241000203353 Methanococcus Species 0.000 description 1
- 241000204675 Methanopyrus Species 0.000 description 1
- 241000202997 Methanothermus Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000282943 Odocoileus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001135648 Petrotoga Species 0.000 description 1
- 241000204826 Picrophilus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000205226 Pyrobaculum Species 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 241000204671 Pyrodictium Species 0.000 description 1
- 241000531151 Pyrolobus Species 0.000 description 1
- 241001148569 Rhodothermus Species 0.000 description 1
- 241000144007 Rubrobacter Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 101000757617 Solanum tuberosum Apyrase Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000508776 Stetteria Species 0.000 description 1
- 241000132988 Stygiolobus Species 0.000 description 1
- 241000205101 Sulfolobus Species 0.000 description 1
- 241000520811 Sulfophobococcus Species 0.000 description 1
- 241000203775 Thermoactinomyces Species 0.000 description 1
- 241001137870 Thermoanaerobacterium Species 0.000 description 1
- 241001647802 Thermobifida Species 0.000 description 1
- 241001331078 Thermobispora Species 0.000 description 1
- 241001626433 Thermobrachium Species 0.000 description 1
- 241001655242 Thermochromatium Species 0.000 description 1
- 241000205188 Thermococcus Species 0.000 description 1
- 241001524191 Thermocrispum Species 0.000 description 1
- 241000186423 Thermodesulfobacterium Species 0.000 description 1
- 241000016204 Thermodesulforhabdus Species 0.000 description 1
- 241001135707 Thermodesulfovibrio Species 0.000 description 1
- 241000317520 Thermohydrogenium Species 0.000 description 1
- 241000588679 Thermomicrobium Species 0.000 description 1
- 241000203640 Thermomonospora Species 0.000 description 1
- 241001135170 Thermonema Species 0.000 description 1
- 241000204667 Thermoplasma Species 0.000 description 1
- 241001133165 Thermopolyspora Species 0.000 description 1
- 241000205204 Thermoproteus Species 0.000 description 1
- 241000204315 Thermosipho <sea snail> Species 0.000 description 1
- 241000531141 Thermosphaera Species 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241001067536 Tropha Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 201000011424 foodborne botulism Diseases 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
- Developing Agents For Electrophotography (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902659.3A GB9902659D0 (en) | 1999-02-05 | 1999-02-05 | Assay with reduced background |
| GB9902659 | 1999-02-05 | ||
| PCT/GB2000/000315 WO2000046357A1 (en) | 1999-02-05 | 2000-02-03 | Assay with reduced background |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2307100A AU2307100A (en) | 2000-08-25 |
| AU774580B2 true AU774580B2 (en) | 2004-07-01 |
Family
ID=10847233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU23071/00A Expired AU774580B2 (en) | 1999-02-05 | 2000-02-03 | Assay with reduced background |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6913896B1 (enExample) |
| EP (1) | EP1151087B1 (enExample) |
| JP (1) | JP2002535985A (enExample) |
| AT (1) | ATE394478T1 (enExample) |
| AU (1) | AU774580B2 (enExample) |
| CA (1) | CA2360779C (enExample) |
| DE (1) | DE60038788D1 (enExample) |
| DK (1) | DK1151087T3 (enExample) |
| ES (1) | ES2304940T3 (enExample) |
| GB (1) | GB9902659D0 (enExample) |
| PT (1) | PT1151087E (enExample) |
| WO (1) | WO2000046357A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9134303B1 (en) | 1998-08-25 | 2015-09-15 | Alere Scarborough, Inc. | ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto |
| US20080096236A1 (en) * | 1998-08-25 | 2008-04-24 | Binax, Inc. | Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof |
| US6824997B1 (en) | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
| GB9902659D0 (en) * | 1999-02-05 | 1999-03-31 | Microbiological Res Authority | Assay with reduced background |
| DE10107083C2 (de) * | 2001-02-13 | 2003-02-20 | Abdulgabar Salama | Pentosan Polysulfat als Ligand zum Nachweis von Prionen |
| GB0406427D0 (en) | 2004-03-22 | 2004-04-21 | Health Prot Agency | Biological indicator |
| GB0508981D0 (en) | 2005-05-03 | 2005-06-08 | Acolyte Biomedica Ltd | Distinguishing cells in a sample |
| JP5164971B2 (ja) * | 2006-04-21 | 2013-03-21 | ピープルバイオ，アイ エヌ シー | 三次元的相互作用を用いてマルチマー形成ポリペプチドのモノマーからマルチマーを分別検出する方法 |
| US10466245B2 (en) | 2008-02-20 | 2019-11-05 | The Secretary Of State For Health | Covalently linked thermostable kinase for decontamination process validation |
| GB0803068D0 (en) * | 2008-02-20 | 2008-03-26 | Health Prot Agency | Cross-linked biological indicator |
| CN102159948B (zh) | 2008-07-22 | 2014-06-25 | 普罗美加公司 | 基于adp检测的发光磷酸转移酶或atp水解酶测定 |
| WO2010062711A1 (en) * | 2008-11-03 | 2010-06-03 | Cytosignet, Inc. | Determining immunoglobulins in non-blood body fluids of neonatal ungulates |
| GB0900151D0 (en) | 2009-01-07 | 2009-02-11 | Health Prot Agency | rapid bioluminescence detection system |
| GB0918016D0 (en) * | 2009-10-14 | 2009-12-02 | Univ Portsmouth | Biosensor |
| JP5705448B2 (ja) * | 2010-03-31 | 2015-04-22 | アクアス株式会社 | 微生物活性の評価方法、および、該評価方法を用いる水系の微生物制御方法 |
| WO2012170998A1 (en) * | 2011-06-10 | 2012-12-13 | Cornell University | Immobilized protein system for rapid and enhanced multiplexed diagnostics |
| GB201115911D0 (en) | 2011-09-14 | 2011-10-26 | Health Prot Agency | Thermostable assay reagents |
| JP5882177B2 (ja) * | 2012-10-19 | 2016-03-09 | 株式会社日立製作所 | 生体物質回収方法及び生体物質回収装置 |
| WO2014143954A2 (en) * | 2013-03-15 | 2014-09-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Biosensor microarray compositions and methods |
| WO2015120147A1 (en) | 2014-02-06 | 2015-08-13 | Scanogen Inc. | Detection units and methods for detecting a target analyte |
| WO2016025843A1 (en) * | 2014-08-15 | 2016-02-18 | Hoope Technologies Corporation | Devices and methods for fluid sample collection and diagnostic testing |
| EP3204509B1 (en) | 2014-10-08 | 2019-07-10 | Promega Corporation | Bioluminescent succinate detection assay |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| WO2019226841A1 (en) | 2018-05-25 | 2019-11-28 | Scanogen Inc. | Detection units and methods for detecting a target analyte |
| EP4159755A4 (en) * | 2020-05-25 | 2024-07-31 | Yokogawa Electric Corporation | Method for detecting target molecule in specimen, and target molecule detection kit |
| EP4157131A4 (en) * | 2020-05-28 | 2024-10-02 | Charm Sciences, Inc. | METHODS AND ASSEMBLIES FOR SAMPLE ANALYSIS |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0304934A2 (de) * | 1987-08-26 | 1989-03-01 | Hunger, Hans-Dieter | Markierte molekulare Sonden, Verfahren zu ihrer Herstellung und ihre Verwendung |
| WO1994006933A1 (fr) * | 1992-09-22 | 1994-03-31 | Lambdatech S.A. | Conjugue destine a la detection et/ou au dosage d'un compose biologique |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4014745A (en) * | 1975-04-30 | 1977-03-29 | Nasa | Application of luciferase assay for ATP to antimicrobial drug susceptibility |
| GB1567606A (en) * | 1976-08-24 | 1980-05-21 | Secr Defence | Glycerokinases |
| US4160817A (en) * | 1976-09-29 | 1979-07-10 | Research Corporation | Application of protein-protein interaction as an assay for the detection of cancer |
| US4446231A (en) * | 1979-10-03 | 1984-05-01 | Self Colin H | Immunoassay using an amplified cyclic detection system |
| US4584272A (en) | 1980-10-09 | 1986-04-22 | Unitika Ltd. | Adenylate kinase and process for the production thereof |
| US4752562A (en) * | 1981-01-23 | 1988-06-21 | Baxter Travenol Laboratories, Inc. | Detection of serum antibody and surface antigen by radial partition immunoassay |
| JPS58155099A (ja) | 1982-03-12 | 1983-09-14 | Unitika Ltd | コリンエステラ−ゼ定量用試薬 |
| US4628031A (en) * | 1984-09-18 | 1986-12-09 | Michigan Biotechnology Institute | Thermostable starch converting enzymes |
| US4656128A (en) | 1985-01-22 | 1987-04-07 | Research Corporation | Modified alkaline phosphatase |
| US4855241A (en) * | 1988-05-26 | 1989-08-08 | Washington University | Tumor diagnostic method |
| US5366871A (en) * | 1991-11-13 | 1994-11-22 | The University Of Utah | Ubiquitin-peptide extensions as enzyme substrates |
| US5395752A (en) * | 1993-03-19 | 1995-03-07 | Ciba Corning Diagnostics Corp. | Long emission wavelength chemiluminescent compounds and their use in test assays |
| US5962637A (en) * | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
| GB9414096D0 (en) * | 1994-07-13 | 1994-08-31 | Secr Defence | Labelled capture assay |
| US5733541A (en) * | 1995-04-21 | 1998-03-31 | The Regent Of The University Of Michigan | Hematopoietic cells: compositions and methods |
| NZ318689A (en) * | 1995-09-14 | 1999-02-25 | Univ California | Prion antibodies specific for native prpsc and use for detecting human prpsc in a source |
| US6150172A (en) * | 1999-01-08 | 2000-11-21 | The United States Of America As Represented By The Secretary Of Agriculture | Method and kit for extracting prion protein |
| GB9902659D0 (en) * | 1999-02-05 | 1999-03-31 | Microbiological Res Authority | Assay with reduced background |
-
1999
- 1999-02-05 GB GBGB9902659.3A patent/GB9902659D0/en not_active Ceased
-
2000
- 2000-02-03 DE DE60038788T patent/DE60038788D1/de not_active Expired - Lifetime
- 2000-02-03 ES ES00901771T patent/ES2304940T3/es not_active Expired - Lifetime
- 2000-02-03 AT AT00901771T patent/ATE394478T1/de active
- 2000-02-03 CA CA2360779A patent/CA2360779C/en not_active Expired - Lifetime
- 2000-02-03 PT PT00901771T patent/PT1151087E/pt unknown
- 2000-02-03 WO PCT/GB2000/000315 patent/WO2000046357A1/en not_active Ceased
- 2000-02-03 US US09/889,520 patent/US6913896B1/en not_active Expired - Lifetime
- 2000-02-03 AU AU23071/00A patent/AU774580B2/en not_active Expired
- 2000-02-03 JP JP2000597417A patent/JP2002535985A/ja active Pending
- 2000-02-03 EP EP00901771A patent/EP1151087B1/en not_active Expired - Lifetime
- 2000-02-03 DK DK00901771T patent/DK1151087T3/da active
-
2005
- 2005-02-25 US US11/065,700 patent/US20050208608A1/en not_active Abandoned
-
2008
- 2008-10-14 US US12/285,766 patent/US20090186368A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0304934A2 (de) * | 1987-08-26 | 1989-03-01 | Hunger, Hans-Dieter | Markierte molekulare Sonden, Verfahren zu ihrer Herstellung und ihre Verwendung |
| WO1994006933A1 (fr) * | 1992-09-22 | 1994-03-31 | Lambdatech S.A. | Conjugue destine a la detection et/ou au dosage d'un compose biologique |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050208608A1 (en) | 2005-09-22 |
| DK1151087T3 (da) | 2008-08-04 |
| PT1151087E (pt) | 2008-08-11 |
| JP2002535985A (ja) | 2002-10-29 |
| CA2360779A1 (en) | 2000-08-10 |
| GB9902659D0 (en) | 1999-03-31 |
| DE60038788D1 (de) | 2008-06-19 |
| CA2360779C (en) | 2010-04-27 |
| EP1151087A1 (en) | 2001-11-07 |
| ES2304940T3 (es) | 2008-11-01 |
| AU2307100A (en) | 2000-08-25 |
| US20090186368A1 (en) | 2009-07-23 |
| ATE394478T1 (de) | 2008-05-15 |
| EP1151087B1 (en) | 2008-05-07 |
| WO2000046357A1 (en) | 2000-08-10 |
| US6913896B1 (en) | 2005-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU774580B2 (en) | Assay with reduced background | |
| US9102976B2 (en) | Biological indicator | |
| Mole et al. | Phage as a diagnostic–the use of phage in TB diagnosis | |
| US9046523B2 (en) | Rapid bioluminescence detection system | |
| WO2012104261A1 (en) | Exonuclease enabled proximity extension assays | |
| Amani et al. | A review approaches to identify enteric bacterial pathogens | |
| CA2373160C (en) | Methods for monitoring eukaryotic cell integrity, growth and/or division | |
| EP0441469A1 (en) | Immunospecific and bioluminescent assay of cellular ATP | |
| HK1097576B (en) | Biological indicator | |
| Murdoch | Development of a Novel Ultra-Sensitive Immunoassay for the Detection of Prion Protein on Surgical Instruments | |
| HK1158272B (en) | Rapid bioluminescence detection system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: THE HEALTH PROTECTION AGENCY Free format text: THE FORMER OWNER WAS: MICROBIOLOGICAL RESEARCH AUTHORITY |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |